Akademik Veri Yönetim Sistemi
Turkiye Klinikleri Journal of Medical Sciences, cilt.41, sa.3, ss.346-352, 2021 (Scopus, TRDizin)
Type 2 diabetes mellitus (T2DM) is among the most common chronic diseases worldwide and prevention of cardiovascular (CV) complications is an important treatment goal in this process. sodium-glucose co-transporter-2 (SGLT2) inhibitors show antidiabetic effects by preventing glucose reabsorption in the proximal tubules of the kidney where glucose is largely reabsorbed. Metabolic adaptations to induced urinary glucose loss include reduced fat mass and more ketone bodies as additional fuel. SGLT2 inhibitors lower glomerular capillary hypertension and hyperfiltration, thereby reducing the physical stress on the filtration barrier, albuminuria, and the oxygen demand for tubular reabsorption. This improves cortical oxygenation, which, together with lesser tubular gluco-toxicity, may preserve tubular function and glomerular filtration rate in the long term. SGLT2 inhibitors may mimic systemic hypoxia and stimulate erythropoiesis, which improves organ oxygen delivery. The heterogeneity of the associations with outcomes of different SGLT2 inhibitors on CV death among patients with T2D and atherosclerotic cardiovascular disease requires further study. Large-scale randomized clinical trials in recent years have suggested that SGLT2 inhibitors can provide clinical benefits and slow the progression of chronic kidney disease in all cases of heart failure (HF), with or without T2DM. In the light of the present results; SGLT2 inhibitors occupy an important place in relevant current guidelines due to their cardiorenal advantages. We aimed to reviews the current role of SGLT2 inhibitors in the treatment of HF and chronic kidney disease.